Tyco Urology Franchise Leaps Ahead With $3.2 Bil. Bard Acquisition
This article was originally published in The Gray Sheet
Executive Summary
Tyco International will increase its total health care sales to about $7.6 bil. annually through acquisition of C.R. Bard for approximately $3.2 bil. in stock. Valued at nearly three times Bard's 2000 sales of $1.1 bil., the definitive agreement was announced May 30.
You may also be interested in...
Tyco Break-Up Positions Health Unit Among Largest U.S. Device Companies
The success of Tyco Healthcare as a stand-alone entity following its spin-off from parent Tyco International may hinge on its ability to continue to move beyond commodity disposable medical products into higher-margin medical device markets
Tyco Break-Up Positions Health Unit Among Largest U.S. Device Companies
The success of Tyco Healthcare as a stand-alone entity following its spin-off from parent Tyco International may hinge on its ability to continue to move beyond commodity disposable medical products into higher-margin medical device markets
Bard Second FTC Information Request May Portend Tyco Divestiture
Bard is confident that its $3.2 bil. acquisition by Tyco will go through by year-end despite the intensified antitrust scrutiny by the Federal Trade Commission.